FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will seek advisory panel input Nov. 3-4 on options for facilitating trials in community-, hospital- and ventilator-acquired pneumonia.
You may also be interested in...
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?
Prior Antibiotic Use A Necessary Confounder In Pneumonia Trials, Panel Says
FDA panel chose practicality over preference in suggesting that trials for hospital- and ventilator-acquired bacterial pneumonia can enroll patients who have previously received antibiotics.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.